Is Krystal Biotech Stock a Good Investment?
Krystal Biotech Investment Advice | KRYS |
- Examine Krystal Biotech's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Krystal Biotech's leadership team and their track record. Good management can help Krystal Biotech navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact Krystal Biotech's business and its evolving consumer preferences.
- Compare Krystal Biotech's performance and market position to its competitors. Analyze how Krystal Biotech is positioned in terms of product offerings, innovation, and market share.
- Check if Krystal Biotech pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Krystal Biotech's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Krystal Biotech stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Krystal Biotech is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Krystal Biotech Stock
Researching Krystal Biotech's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 12.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years.
To determine if Krystal Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Krystal Biotech's research are outlined below:
| Over 88.0% of the company shares are owned by institutional investors |
Krystal Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Krystal Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Krystal Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of February 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Krystal Biotech's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.44 B.Krystal Biotech's profitablity analysis
The company has Profit Margin (PM) of 0.31 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.45 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.45.Determining Krystal Biotech's profitability involves analyzing its financial statements and using various financial metrics to determine if Krystal Biotech is a good buy. For example, gross profit margin measures Krystal Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Krystal Biotech's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Krystal Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Krystal Biotech. Check Krystal Biotech's Beneish M Score to see the likelihood of Krystal Biotech's management manipulating its earnings.
Basic technical analysis of Krystal Stock
As of the 22nd of March, Krystal Biotech secures the Downside Deviation of 2.15, risk adjusted performance of 0.1022, and Mean Deviation of 1.87. Krystal Biotech technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Krystal Biotech standard deviation, as well as the relationship between the value at risk and kurtosis to decide if Krystal Biotech is priced some-what accurately, providing market reflects its recent price of 187.15 per share. Given that Krystal Biotech has jensen alpha of 0.2586, we recommend you to check Krystal Biotech's last-minute market performance to make sure the company can sustain itself at a future point.Krystal Biotech's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Krystal Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Krystal Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Krystal Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Krystal Biotech's Outstanding Corporate Bonds
Krystal Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Krystal Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Krystal bonds can be classified according to their maturity, which is the date when Krystal Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Krystal Biotech's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Krystal Biotech's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1022 | |||
| Market Risk Adjusted Performance | (1.41) | |||
| Mean Deviation | 1.87 | |||
| Semi Deviation | 1.97 | |||
| Downside Deviation | 2.15 | |||
| Coefficient Of Variation | 927.61 | |||
| Standard Deviation | 2.61 | |||
| Variance | 6.82 | |||
| Information Ratio | 0.1298 | |||
| Jensen Alpha | 0.2586 | |||
| Total Risk Alpha | 0.4698 | |||
| Sortino Ratio | 0.1574 | |||
| Treynor Ratio | (1.42) | |||
| Maximum Drawdown | 16.57 | |||
| Value At Risk | (3.51) | |||
| Potential Upside | 3.4 | |||
| Downside Variance | 4.63 | |||
| Semi Variance | 3.89 | |||
| Expected Short fall | (2.17) | |||
| Skewness | 1.46 | |||
| Kurtosis | 6.68 |
| Risk Adjusted Performance | 0.1022 | |||
| Market Risk Adjusted Performance | (1.41) | |||
| Mean Deviation | 1.87 | |||
| Semi Deviation | 1.97 | |||
| Downside Deviation | 2.15 | |||
| Coefficient Of Variation | 927.61 | |||
| Standard Deviation | 2.61 | |||
| Variance | 6.82 | |||
| Information Ratio | 0.1298 | |||
| Jensen Alpha | 0.2586 | |||
| Total Risk Alpha | 0.4698 | |||
| Sortino Ratio | 0.1574 | |||
| Treynor Ratio | (1.42) | |||
| Maximum Drawdown | 16.57 | |||
| Value At Risk | (3.51) | |||
| Potential Upside | 3.4 | |||
| Downside Variance | 4.63 | |||
| Semi Variance | 3.89 | |||
| Expected Short fall | (2.17) | |||
| Skewness | 1.46 | |||
| Kurtosis | 6.68 |
Consider Krystal Biotech's intraday indicators
Krystal Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Krystal Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Krystal Biotech time-series forecasting models is one of many Krystal Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Krystal Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Krystal Stock media impact
Far too much social signal, news, headlines, and media speculation about Krystal Biotech that are available to investors today. That information is available publicly through Krystal media outlets and privately through word of mouth or via Krystal internal channels. However, regardless of the origin, that massive amount of Krystal data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Krystal Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Krystal Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Krystal Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Krystal Biotech alpha.
Krystal Biotech Corporate Management
| Christine Wilson | Head Marketing | Profile | |
| David Chien | Senior Development | Profile | |
| Hubert MD | Senior Development | Profile | |
| Gloria Lin | Accounting Mang | Profile | |
| Kathryn Romano | Executive Officer | Profile | |
| Katherine Tuminello | HR Mang | Profile |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.